Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with HER2-altered Tumours, Including NSCLC By Ogkologos - March 17, 2025 562 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR New Treatment Combinations Slow Progression of Prostate Cancer and Stomach and... February 5, 2024 Patient Guide on Immunotherapy Side Effects and Their Management Now Available... November 26, 2025 4 Tips from Oncology Dietitians for Healthier Eating During Cancer January 2, 2024 Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or... February 19, 2026 Load more HOT NEWS FDA Grants Accelerated Approval to Infigratinib for Metastatic Cholangiocarcinoma Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated... Finding Purpose in Sharing Your Story: A Q&A With Esophageal Cancer... ctDNA Analysis is Feasible for Detection of Minimal Residual Disease After...
